70
Participants
Start Date
September 2, 2017
Primary Completion Date
November 30, 2024
Study Completion Date
November 30, 2024
Pembrolizumab
200 mg Given IV
Carboplatin
Arm A: AUC 5 IV every 3 weeks Arm B: AUC 5 IV every 3 weeks
Trastuzumab
For HER2+ patients: IV every 3 weeks using standard approved dosing
University of Pittsburgh Cancer Institute, Pittsburgh
Georgetown University Hospital, Washington D.C.
Vanderbilt University/Ingram Cancer Center, Nashville
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
University of Chicago Comprehensive Cancer Center, Chicago
University of California, San Francisco, San Francisco
Massachusetts General Hospital, Boston
Collaborators (1)
Mayo Clinic
OTHER
Johns Hopkins University
OTHER
Translational Breast Cancer Research Consortium
OTHER
Massachusetts General Hospital
OTHER
Merck Sharp & Dohme LLC
INDUSTRY
Laura Huppert, MD, BA
OTHER